Limits...
Low utilisation of diabetes medicines in Iran, despite their affordability (2000-2012): a time-series and benchmarking study.

Sarayani A, Rashidian A, Gholami K - BMJ Open (2014)

Bottom Line: Regular and isophane insulin (NPH), glibenclamide, metformin and gliclazide were the DU-90 drugs in 2012.Metformin, glibenclamide and regular/NPH insulin combination therapy were affordable throughout the study period (∼0.4, ∼0.1, ∼0.3 of minimum daily wage, respectively).While the affordability of novel insulin preparations improved over time, they were still unaffordable in 2012.

View Article: PubMed Central - PubMed

Affiliation: Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran.

Show MeSH

Related in: MedlinePlus

Benchmarking the trend of diabetes drugs utilisation (Iran and OECD countries with comparable diabetes prevalence according to IDF statistics). DDD, defined daily dose; IDF, International Diabetes Federation; OECD, Organization for Economic Co-operation and Development.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4202013&req=5

BMJOPEN2014005859F4: Benchmarking the trend of diabetes drugs utilisation (Iran and OECD countries with comparable diabetes prevalence according to IDF statistics). DDD, defined daily dose; IDF, International Diabetes Federation; OECD, Organization for Economic Co-operation and Development.

Mentions: Benchmarking with OECD countries showed that Iran had a low A10 utilisation in 2011 (figure 3). The prevalence of diabetes in Australia, Finland, Germany, Spain and Estonia were similar to Iran in 2011 (8–10%). The utilisation of A10 medicines increased in all of these countries from 2000 to 2011 but the magnitude of growth was highest in Iran (430.7%). Nevertheless, the annual per capita A10 utilisation in Iran was consistently and substantially lower than those five countries during the benchmarking period (figure 4).


Low utilisation of diabetes medicines in Iran, despite their affordability (2000-2012): a time-series and benchmarking study.

Sarayani A, Rashidian A, Gholami K - BMJ Open (2014)

Benchmarking the trend of diabetes drugs utilisation (Iran and OECD countries with comparable diabetes prevalence according to IDF statistics). DDD, defined daily dose; IDF, International Diabetes Federation; OECD, Organization for Economic Co-operation and Development.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4202013&req=5

BMJOPEN2014005859F4: Benchmarking the trend of diabetes drugs utilisation (Iran and OECD countries with comparable diabetes prevalence according to IDF statistics). DDD, defined daily dose; IDF, International Diabetes Federation; OECD, Organization for Economic Co-operation and Development.
Mentions: Benchmarking with OECD countries showed that Iran had a low A10 utilisation in 2011 (figure 3). The prevalence of diabetes in Australia, Finland, Germany, Spain and Estonia were similar to Iran in 2011 (8–10%). The utilisation of A10 medicines increased in all of these countries from 2000 to 2011 but the magnitude of growth was highest in Iran (430.7%). Nevertheless, the annual per capita A10 utilisation in Iran was consistently and substantially lower than those five countries during the benchmarking period (figure 4).

Bottom Line: Regular and isophane insulin (NPH), glibenclamide, metformin and gliclazide were the DU-90 drugs in 2012.Metformin, glibenclamide and regular/NPH insulin combination therapy were affordable throughout the study period (∼0.4, ∼0.1, ∼0.3 of minimum daily wage, respectively).While the affordability of novel insulin preparations improved over time, they were still unaffordable in 2012.

View Article: PubMed Central - PubMed

Affiliation: Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran.

Show MeSH
Related in: MedlinePlus